PeopleBio. Inc.

PeopleBio. Inc.

KKRX:304840
561.00
KRW
-9.00
(-1.58%)
-555.41EPS
19.19BMarket Cap
PeopleBio. Inc.
KRX:304840
(Korea Stock Exchange)

Recent

price

561.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
- -
- -
3.94
65.17
18.04
36.06
262.23
268.54
116.41
130.97
170.61
Revenue per Share
-5,248.89
-611.46
-272.28
-291.35
-155.74
-293.5
-843.82
-967
-502
-722
-718.2
Basic EPS, GAAP
-3,032.52
-258.8
-188.84
-195.78
-131.44
-513.83
-903.51
-1,027.76
-507.18
-252.99
-239.79
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-684.23
112.98
357.99
178.68
567.27
1,068.27
231.72
894.97
382.52
1,337.86
1,159.61
Book Value per Share
-689.33
108.7
354.43
175.94
562.45
836.62
30.01
753.25
256.97
1,337.72
1,159.5
Tangible Book Value per Share
1
7
13
14
28
16
17
17
22
22
21
Basic Weighted Avg Shares
- -
- -
51
895
508
577
4,445
4,453
2,531
2,851
3,651
Sales/Revenue/Turnover
- -
- -
-7,347.05
-453.79
-896.78
-1,253.81
-263.16
-342.42
-340.7
-291.66
-163.72
Operating Margin (%)
19
28
101
264
284
734
1,282
1,565
1,692
1,747
958
Depreciation Expense
-3,489
-4,236
-3,545
-4,001
-4,383
-4,697
-14,303
-16,035
-10,913
-15,714
-15,369
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-6,912.77
-447.04
-863.09
-813.94
-321.79
-360.1
-431.25
-551.26
-420.95
Profit Margin (%)
-10,423
1,806
5,986
3,364
9,592
10,879
-3,495
11,276
522
-9,664
-75,846
Working Capital
- -
- -
- -
173
71
1,036
1,385
1,114
291
49
152
LT Debt
-10,348
1,709
5,414
2,702
8,828
19,016
5,924
19,664
7,621
28,618
28,820
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-99.56
-98.6
-76.03
-36.91
-140.14
-141.83
-81.08
-86.29
-94.36
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7,707
13,083
76,339
LT Borrowings
- -
- -
- -
LT Finance Leases
49
23
152
Preferred Equity and Hybrid Capital
295
295
- -
Shares Outstanding
21
23
25
Market Capitalization
22,631
17,446
19,186

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,357
7,197
3,466
Cash, Cash Equivalents & STI
80
2,988
302
Accounts Receivable, Net
1,267
1,079
907
Inventories
1,816
1,564
1,101
Total Current Liabilities
14,021
15,754
79,312
Payables & Accruals
- -
- -
- -
ST Debt
7,707
13,083
76,339
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
98.56%
275.53%
Free Cash Flow
- -
26.89%
-50.06%
Net Income, GAAP
- -
47.17%
43.99%
Sales/Revenue/Turnover
- -
130.7%
12.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
744
1,367
962
658
2,531
2025
622
704
1,185
154
2,851
2026
643
1,669
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-145.68
-138
-141
-79.79
-502
2025
-132
-67
-51.54
-484.15
-722
2026
-92.5
-95
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
PeopleBio, Inc. is a South Korea-based biotechnology and in vitro diagnostics company specializing in the development of blood-based diagnostic assays and screening tools for neurodegenerative diseases and protein-misfolding disorders. The company develops and commercializes diagnostic products powered by its proprietary Multimer Detection System (MDS) platform, which selectively detects and measures oligomeric and aggregated multimeric proteins in human plasma. PeopleBio operates primarily in the medical devices and molecular diagnostics sector, serving hospitals, commercial clinical laboratories, specialized clinics, and health screening centers. The company's product and service portfolio includes in vitro diagnostic test kits for neurodegenerative conditions, notably the InBlood / InSparq Alzheimer's disease blood test kit designed for the early detection and risk assessment of Alzheimer's disease through the quantification of oligomeric amyloid-beta (OA-beta) in blood plasma; research-use and clinical diagnostic assays targeting alpha-synuclein multimers for the early detection and monitoring of Parkinson's disease; diagnostic development pipelines for tau protein aggregation, amyotrophic lateral sclerosis (ALS), and diabetes-related neurodegenerative pathologies; specialized laboratory diagnostic testing and sample analysis services for healthcare institutions; and digital healthcare applications supporting cognitive screening and preventive memory health management. In recent strategic and operational developments, PeopleBio has actively expanded its commercialization footprint for its blood-based Alzheimer's diagnostic assay across domestic and international markets. The company has secured supply and distribution agreements across several Asia-Pacific markets, including Southeast Asian territories, while pursuing regulatory approvals and clinical partnerships in Europe and North America to facilitate global market entry. Additionally, PeopleBio has advanced clinical evaluations for its early-stage Parkinson's disease blood diagnostic pipeline and expanded collaborations with healthcare networks, diagnostic centers, and digital health partners to integrate blood-based biomarker screening into routine health examination programs. Founded in 2002, PeopleBio, Inc. is headquartered in Seongnam-si, Gyeonggi-do, South Korea, and is listed on the Korean Securities Dealers Automated Quotations (KOSDAQ) under the ticker symbol 304840.